Physician profile
Russ Robert Ayers
NPI 1457556557
$12,294.47
in general payments reported to CMS, 2019-2025
31 companies · $9,485 in 2025
The $9,485 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $295 · 2020: $77.19 · 2021: $379 · 2022: $896 · 2023: $590 · 2024: $572 · 2025: $9,485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,925 · Food and Beverage: $1,722.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,925.00 |
| Food and Beverage | $1,722.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Plasma INC. | $8,925.00 | 2025 | |
| Viiv Healthcare Company | $620.63 | 2019-2025 | Cabenuva, Dovato |
| Abbvie INC. | $387.70 | 2021-2025 | Vraylar |
| Merck Sharp & Dohme LLC | $355.36 | 2019-2025 | Delstrigo, Pifeltro, Verquvo |
| Novo Nordisk INC | $296.68 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $209.90 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $209.19 | 2021-2024 | Mounjaro |
| Pfizer INC. | $150.63 | 2019-2023 | |
| Theratechnologies INC. | $134.05 | 2022-2023 | Egrifta, Trogarzo |
| Glaxosmithkline, LLC. | $119.32 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $102.70 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $95.67 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.88 | 2024-2025 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $76.00 | 2019-2023 | |
| Gilead Sciences, INC. | $71.73 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $63.39 | 2021-2023 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $59.89 | 2022 | |
| Amgen INC. | $57.92 | 2021-2022 | |
| Corcept Therapeutics | $51.97 | 2025 | Korlym |
| Boston Scientific Corporation | $38.93 | 2019 | |
| Janssen Pharmaceuticals, INC | $37.86 | 2021 | |
| Emd Serono, INC. | $23.77 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.86 | 2024 | Caplyta |
| Corium, LLC | $17.25 | 2021 | |
| Janssen Biotech, INC. | $15.86 | 2022 | |
| Shield Therapeutics INC | $14.57 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $12.79 | 2022 | |
| Sanofi Pasteur INC. | $11.96 | 2019 | |
| Allergan, INC. | $11.40 | 2019 | |
| Amarin Pharma, INC. | $11.31 | 2021 | |
| Abbott Laboratories | $11.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russ Ayers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.